Reuters logo
9 个月前
BRIEF-PhaseRx receives orphan drug designation from FDA for PRX-OTC
2016年11月28日 / 下午1点47分 / 9 个月前

BRIEF-PhaseRx receives orphan drug designation from FDA for PRX-OTC

1 分钟阅读

Nov 28 (Reuters) - PhaseRx Inc -

* Phaserx receives orphan drug designation from FDA for PRX-OTC for the treatment of ornithine transcarbamylase deficiency

* PRX-OTC, which is being developed for treatment of ornithine transcarbamylase deficiency has received orphan drug designation by U.S. FDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below